Wu Xianzhu, Dayanand Kiran K, Thylur Ramesh P, Norbury Christopher C, Gowda D Channe
From the Departments of Biochemistry and Molecular Biology and.
Microbiology and Immunology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033.
J Biol Chem. 2017 Aug 18;292(33):13615-13634. doi: 10.1074/jbc.M116.770313. Epub 2017 Jul 5.
Malaria infections cause several systemic and severe single- or multi-organ pathologies, killing hundreds of thousands of people annually. Considering the existing widespread resistance of malaria parasites to anti-parasitic drugs and their high propensity to develop drug resistance, alternative strategies are required to manage malaria infections. Because malaria is a host immune response-driven disease, one approach is based on gaining a detailed understanding of the molecular and cellular processes that modulate malaria-induced innate and adaptive immune responses. Here, using a mouse cerebral malaria model and small-molecule inhibitors, we demonstrate that inhibiting MEK1/2, the upstream kinases of ERK1/2 signaling, alters multifactorial components of the innate and adaptive immune responses, controls parasitemia, and blocks pathogenesis. Specifically, MEK1/2 inhibitor treatment up-regulated B1 cell expansion, IgM production, phagocytic receptor expression, and phagocytic activity, enhancing parasite clearance by macrophages and neutrophils. Further, the MEK1/2 inhibitor treatment down-regulated pathogenic pro-inflammatory and helper T cell 1 (Th1) responses and up-regulated beneficial anti-inflammatory cytokine responses and Th2 responses. These inhibitor effects resulted in reduced granzyme B expression by T cells, chemokine and intracellular cell adhesion molecule 1 (ICAM-1) expression in the brain, and chemokine receptor expression by both myeloid and T cells. These bimodal effects of the MEK1/2 inhibitor treatment on immune responses contributed to decreased parasite biomass, organ inflammation, and immune cell recruitment, preventing tissue damage and death. In summary, we have identified several previously unrecognized immune regulatory processes through which a MEK1/2 inhibitor approach controls malaria parasitemia and mitigates pathogenic effects on host organs.
疟疾感染会引发多种全身性和严重的单器官或多器官病变,每年导致数十万人死亡。鉴于疟原虫对抗寄生虫药物普遍存在耐药性,且极易产生耐药性,因此需要采取替代策略来控制疟疾感染。由于疟疾是一种由宿主免疫反应驱动的疾病,一种方法是深入了解调节疟疾诱导的先天性和适应性免疫反应的分子和细胞过程。在此,我们使用小鼠脑型疟疾模型和小分子抑制剂,证明抑制ERK1/2信号通路的上游激酶MEK1/2,可改变先天性和适应性免疫反应的多因素成分,控制寄生虫血症,并阻断发病机制。具体而言,MEK1/2抑制剂治疗上调了B1细胞扩增、IgM产生、吞噬受体表达和吞噬活性,增强了巨噬细胞和中性粒细胞对寄生虫的清除。此外,MEK1/2抑制剂治疗下调了致病性促炎和辅助性T细胞1(Th1)反应,上调了有益的抗炎细胞因子反应和Th2反应。这些抑制剂作用导致T细胞中颗粒酶B表达减少,大脑中趋化因子和细胞内细胞黏附分子1(ICAM-1)表达减少,以及髓样细胞和T细胞中趋化因子受体表达减少。MEK1/2抑制剂治疗对免疫反应的这种双重作用有助于减少寄生虫数量、器官炎症和免疫细胞募集,防止组织损伤和死亡。总之,我们确定了几个以前未被认识的免疫调节过程,通过这些过程,MEK1/2抑制剂方法可控制疟疾寄生虫血症,并减轻对宿主器官的致病作用。